wonders why people would sell , page-10

http://www.upi.com/Top_News/World-News/2011/04/01/Putin-orders-Russian-biotech-plan-by-May/UPI-82221301673754/

The rat race is on for countries to expand their presence within the biotech sector. This firstly shows the recognition of an expanding market. Which in turn means greater potential for the likes of GSK to push harder and more aggressively in flooding the markets with their products. This will also mean greater competition but with the market reach, excellent R&D team and experience the big pharma's of the world will IMO have the upper hand in the new markets.

This is of course talk of the long term goals. But according to the FMCG-2 announcement it fits in perfectly. Beacause they have just hopped onboard it will still be a fairly long journey ahead. It was mentioned that there will be an initial 5-year strategic alliance to develop a wide range of products. If it should go well then once the products are commercialised then OBJ will receive royalties for 5 years or the life of the patent, which ever is longer. So going off that announcement we still have a good 5 years left before we get any commercialised products from them (micro array), FIM technology however shouldn't take as long.

With FMCG-1 and GSK being close to finishing development and commercialising their product we can have revenue from them and if FMCG-2 should be favourable, extended revenue in the long term. But that all depends on the product life circle of FMCG-1 and GSK's commercialised product.